Takeda Oncology

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Administration, Head, TIL, Colorectal cancer, Immunotherapy, HNSCC, Takeda Oncology, Selection, Patient, G&A, Melanoma, TILS, Investment, CRC, Breast cancer, SITC, Research and development, Research institute, Turnstone, Uveal melanoma

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “2023 marked a transformative year for Turnstone Biologics in which we transitioned into a publicly traded company and continued to advance our pipeline through clinical development.
  • Recently, Turnstone expanded their trials to evaluate additional solid tumor types in addition to the existing indications of breast cancer and uveal melanoma.
  • Preclinical Data Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Support Ongoing Clinical and Preclinical Efforts.
  • Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Retrieved on: 
Tuesday, March 19, 2024
American University, SAN, CDT, Research, Conduit, Pfizer, University, Doctor of Philosophy, Chemistry, Patent, CSO, Takeda Oncology, Pharmaceutical industry

SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) --  Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.

Key Points: 
  • SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) --  Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.
  • Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum.
  • Dr. Holland earned a PhD in chemistry from the University of Leeds, UK, which was sponsored by Pfizer, Inc., before starting her career at companies including Millennium Pharmaceuticals and Stylacats Limited.
  • “The appointment of Jo as Chief Scientific Officer underscores Conduit’s commitment to optimizing the value of our current intellectual property assets, while concurrently fostering the creation of new intellectual property,” said Dr. David Tapolczay, Chief Executive Officer.

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Software, Artificial Intelligence, Clinical Trials, Translational research, Australian National University, Communication, Corbus, Associate, Takeda Oncology, University, Research, Artificial intelligence, Cancer, Head, Doctor of Philosophy, Molecular biology, Medicine, Biochemistry, Brake, Takeda, Medical research, Interim, Multimedia, Zephyr, Medical device

Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer.

Key Points: 
  • Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240401145891/en/
    “Having spent decades working in big pharma and biotech spanning roles in research, development and commercial, Rachael comes to Zephyr with a unique breadth of experience,” said Jeff Sherman, Zephyr AI Co-Founder, Interim CEO, and Chief Technology Officer.
  • Prior to her work at Corbus, Brake spent 11 years at Takeda Oncology, most recently as Head of U.S. Medical Affairs Oncology.
  • I’m thrilled to be joining the incredibly talented Zephyr AI team at such a pivotal time in clinical research.”

Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Principal, RAPS, University, Science, Atlas, ARCH Venture Partners, Drug discovery, Patient, Biogen, Molecular biology, Senior advisor, Biochemistry, Therapy, DSM-IV codes, RNA interference, Atlas Venture, Multimedia, Third Rock Ventures, Takeda Oncology, Biotechnology Innovation Organization, Pharmaceutical industry

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240319245625/en/
    “As Rapport sets out to build a leading precision neuroscience company, we are incredibly fortunate to have Dr. Maraganore join our board,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • “John is among a few visionary leaders who have guided a new modality from concept to a dynamic platform for drug discovery.
  • Dr. Maraganore served as founding CEO of Alnylam from 2002 to 2021, where he led the development of a novel class of medicines, referred to as RNAi therapeutics.

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Stromal cell, Amgen, American Chemical Society, University, Cornell University, Patient, Medicinal chemistry, Indiana University, Whitehead Institute, Doctor of Philosophy, Therapy, Drug development, Pharmacy, Division, Molecular biology, Takeda Oncology, Ironwood Pharmaceuticals, Pharmaceutical industry

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Key Points: 
  • Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.
  • Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.
  • He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018.
  • "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

OcuSciences Welcomes Michael Patane, PhD, to its Board of Directors

Retrieved on: 
Tuesday, February 20, 2024
Medical Devices, Health, Diabetes, Pharmaceutical, Optical, Biotechnology, Therapy, Acquisition, Doctor of Philosophy, Drug discovery, Mitochondrion, History, Biomedical Research, DSM-IV codes, Knowledge, Takeda Oncology, Medicinal chemistry, Pharmaceutical industry

OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the addition of Michael Patane, PhD, to its Board of Directors.

Key Points: 
  • OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the addition of Michael Patane, PhD, to its Board of Directors.
  • "We are thrilled to welcome Dr. Michael Patane to our Board of Directors," said Kurt Riegger, CEO at OcuSciences.
  • “OcuSciences is at a very exciting time in its history as it builds momentum around its novel and patented retinal disease detection modality,” said Dr. Michael Patane.
  • “I am honored to join this Board and look forward to working with my fellow directors and senior management to help OcuSciences advance the development and commercialization of its transformative retinal imaging devices.”

Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors

Retrieved on: 
Tuesday, January 30, 2024
PGI, Genetics, School, Head, MD, Patient, Biotechnology, Investment, Corporation, MBA, Takeda, SVP, Vice president, Drug development, Acquisition, Hematology, Genetic code, Takeda Oncology, Takeda Pharmaceutical Company, University, Millennium, Pharmaceutical industry

WATERTOWN, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the appointment of Daniel Curran, MD, to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the appointment of Daniel Curran, MD, to its Board of Directors.
  • Dr. Curran was most recently Head of Rare Genetics and Hematology at Takeda Pharmaceuticals.
  • “Dan has a storied corporate and drug development career, stretching from his tenure at Millennium through to leadership at Takeda.
  • Notably, Dan oversaw the integration of Shire after its acquisition by Takeda, then leading development and execution of Takeda’s rare disease portfolio strategy,” said Rahul Kakkar, MD, President and CEO of Tome Biosciences.

Remix Therapeutics Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, February 1, 2024
Biomedicine, Senior, RNA, Science, History, Harvard University, University, Third Rock Ventures, Patient, Drug discovery, Entrepreneurship, Doctor of Philosophy, Disease, CSO, Takeda Oncology

WATERTOWN, Mass., Feb. 1, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Dominic Reynolds, Ph.D., as Chief Scientific Officer (CSO). Dr. Reynolds has been with Remix since its inception in 2019 and has been promoted from his previous role as Senior Vice President, Head of Drug Discovery, where he led the design and synthesis of compounds to reformat RNA.

Key Points: 
  • Dr. Reynolds brings over two decades of leadership experience building biotech companies, transformative platforms and drug discovery and development
    WATERTOWN, Mass., Feb. 1, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Dominic Reynolds, Ph.D., as Chief Scientific Officer (CSO).
  • As part of this planned leadership transition, former CSO Zaven Kaprielian, Ph.D., will join Remix's Scientific Advisory Board, where he will continue to advise on Remix's evolving science and pipeline.
  • "Dominic has been an invaluable member of the Remix team since company inception, and his deep expertise in drug discovery has advanced Remix's pipeline of RNA processing modulators forward.
  • Previous positions include drug discovery roles at Third Rock Ventures, Forma Therapeutics, a company he also joined on day one, and Millennium Pharmaceuticals.